Leflunomide: Friend or foe for systemic lupus erythematosus?

Rheumatology International

Volumn 33, Issue 2, 2013, Pages 273-276

  Wu, Guo Cui ^a   Xu, Xiao Di ^a   Huang, Qiong ^a   Wu, Hua ^a  

^a Hefei First People s Hospital   (China)

Author keywords

Leflunomide; Systemic lupus erythematosus; Therapy

Indexed keywords

CYCLOPHOSPHAMIDE; LEFLUNOMIDE; PLACEBO; PREDNISONE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; AUTOIMMUNITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; HYPERTENSION; INFECTION; LEUKOPENIA; PRIORITY JOURNAL; PSEUDOPSEUDO MEIGS SYNDROME; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; AUTOIMMUNITY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 84873987937     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-012-2508-z     Document Type: Review

References (37)

1. Smolen JS, Graninger WB, Emery P (2000) Leflunomide, a new disease-modifying anti-rheumatic drug and the never ending rheumatoid arthritis story. Rheumatology (Oxford) 39:689-692
2. Strand V, Cohen S, Schiff M et al (1999) Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 159:2542-2550
3. Smolen JS, Kalden JR, Scott DL et al (1999) Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 353:259-266
4. Emery P, Breedveld FC, Lemmel EM et al (2000) A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 39:655-665
5. Breedveld FC, Dayer JM (2000) Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 59:841-849
6. Popovic S, Bartlett RR (1987) The use of the murine chronic graft vs host (CGVH) disease, a model for systemic lupus erythematosus (SLE), for drug discovery. Agents Actions 21:284-286
7. Bartlett RR, Popovic S, Raiss RX (1988) Development of autoimmunity in MRL/lpr mice and the effects of drugs on this murine disease. Scand J Rheumatol Suppl 75:290-299
8. Petera P, Manger B, Rosenburg R et al (2000) A pilot study of leflunomide in systemic lupus erythematosus (SLE). Arthritis Rheum 43:S241
9. Remer CF, Weisman MH, Wallace DJ (2001) Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus 10:480-483
10. Petri M (2001) High dose arava in lupus (HAIL). Arthritis Rheum 44:S280
11. Kessel A, Toubi E (2002) Leflunomide in systemic lupus erythematosus. Harefuah 141:355-357
12. Tam LS, Li EK, Wong CK et al (2004) Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus 13:601-604
13. Cui TG, Hou FF, Ni ZH et al (2005) Treatment of proliferative lupus nephritis with leflunomide and steroid: a prospective multi-center controlled clinical trial. Zhonghua Nei Ke Za Zhi 44:672-676 [In Chinese]
14. Tam LS, Li EK, Wong CK et al (2006) Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial. Ann Rheum Dis 65:417-418
15. Wang HY, Cui TG, Hou FF et al (2008) Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study. Lupus 17:638-644
16. Holm EA, Balslev E, Jemec GB (2001) Vasculitis occurring during leflunomide therapy. Dermatology 203:258-259
17. Carulli MT, Davies UM (2002) Peripheral neuropathy: an unwanted effect of leflunomide? Rheumatology 41:952-953
18. Soliotis F, Glover M, Jawad AS (2002) Severe skin reaction after leflunomide and etanercept in a patient with rheumatoid arthritis. Ann Rheum Dis 61:850-851
19. Chan AT, Bradlow A, McNally J (2003) Leflunomide induced vasculitisea dose-response relationship. Rheumatology 42:492-493
20. Fischer TW, Bauer HI, Graefe T et al (2003) Erythema multiforme-like drug eruption with oral involvement after intake of leflunomide. Dermatology 207:386-389
21. van Roon EN, Jansen TL et al (2004) Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity. Drug Saf 27:345-352
22. Chan J, Sanders DC, Du L et al (2004) Leflunomide associated pancytopenia with or without methotrexate. Ann Pharmacother 38:1206-1211
23. Bharadwaj A, Haroon N (2004) Peripheral neuropathy in patients on leflunomide. Rheumatology 43:934
24. Bonnel RA, Graham DJ (2004) Peripheral neuropathy in patients treated with leflunomide. Clin Pharmacol Ther 75:580-585
25. Kamata Y, Nara H, Kamimura T et al (2004) Rheumatoid arthritis complicated with acute intersitial pneumonia induced by leflunomide as an adverse reaction. Intern Med 43:1201-1204
26. Kerr OA, Murray CS, Tidman MJ (2004) Subacute cutaneous lupus erythematosus associated with leflunomide. Clin Exp Dermatol 29:319-320
27. Goeb V, Berhelot JM, Joly P et al (2005) Leflunomide-induced subacute cutaneous lupus erythematosus. Rheumatology 44:823-824
28. Gensburger D, Kawashima M, Marotte H et al (2005) Lupus erythematosus with leflunomide: induction or reactivation? Ann Rheum Dis 64:153-155
29. Takeishi M, Akiyama Y, Akiba H et al (2005) Leflunomide induced acute interstitial pneumonia. J Rheumatol 32:1160-1163
30. Fox RI, Herrmann ML, Frangou CG et al (1999) Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 93:198-208
31. González-Alvaro I, Ortiz AM, Domínguez-Jiménez C et al (2009) Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK/STAT pathway. Ann Rheum Dis 68:1644-1650
32. Manna SK, Mukhopadhyay A, Aggarwal BB (2000) Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J Immunol 165:5962-5969
33. Manna SK, Aggarwal BB (1999) Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J Immunol 162:2095-2102
34. He C, Lu X, Yan Z et al (2012) Therapeutic effect of leflunomide on the development of experimental lupus nephritis in mice. Rheumatol Int 32:633-638
35. Bes C, Soy M (2011) Pseudo-pseudo Meigs syndrome developed under the leflunomide therapy. Rheumatol Int 31:521-523
36. Suess A, Sticherling M (2008) Leflunomide in subacute cutaneous lupus erythematosus-two sides of a coin. Int J Dermatol 47:83-86
37. Chan SK, Hazleman BL, Burrows NP (2004) Subacute cutaneous lupus erythematosus precipitated by leflunomide. Clin Exp Dermatol 29:724-725